The challenge of hepatitis C in the HIV-infected person

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 473-485

  Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coinfection; HCV; Injection drug use; Liver disease

Indexed keywords

ALPHA2A INTERFERON; ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; AUSTRALIA; CAUSE OF DEATH; DISEASE ASSOCIATION; DRUG FATALITY; DRUG WITHDRAWAL; EUROPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIVER FAILURE; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 39649113866     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.081906.081110     Document Type: Review

References (58)

1. Sherman KE, Rouster SD, Chung RT, et al. 2002. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult MDS Clinical Trials Group. Clin. Infect. Dis. 34:831-37
2. Friis-Moller N, Weber R, Reiss P, et al. 2003. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the D:A:D study. AIDS 17:1179-93
3. Sulkowski MS, Thomas DL. 2003. Hepatitis C in the HIV-infected person. Ann. Intern. Med. 138:197-207
4. Gerberding JL. 1994. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J. Infect. Dis. 170:1410-17
5. Villano SA, Vlahov D, Nelson KE, et al. 1999. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908-14
6. Luetkemeyer A, Hare CB, Stansell J, et al. 2006. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir. Immune Defic. Syndr. 41:31-36
7. Danta M, Brown D, Bhagani S, et al. 2007. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21:983-91
8. Fischer M, Richardson D, Sabin C. 2007. Poster 130. Conf. Retroviruses Opportunistic Infect., 14th, Los Angeles, CA, Feb. 25-28
9. Bodsworth NJ, Cunningham P, Kaldor J, et al. 1996. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin. Med. 72:118-22
10. Goedert JJ, Chen BE, Preiss L, et al. 2007. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am. J. Epidemiol. 165:1443-53
11. Eyster ME, Alter HJ, Aledort LM, et al. 1991. Heterosexual cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann. Intern. Med. 115:764-68
12. Zanetti AR, Tanzi E, Paccagnini S, et al. 1995. Mother-to-infant transmission of hepatitis C virus. Lancet 345:289-91
13. Hershow RC, Riester KA, Lew J, et al. 1997. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. J. Infect. Dis. 176:414-20
14. Thomas DL, Villano SA, Riester KA, et al. 1998. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J. Infect. Dis. 177:1480-88
15. Thomas DL, Astemborski J, Rai RM, et al. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450-56
16. Mehta SH, Cox A, Hoover DR, et al. 2002. Protection against persistence of hepatitis C. Lancet 359:1478-83
17. Thomas DL, Shih JW, Alter HJ, et al. 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J. Infect. Dis. 174:690-95
18. Goedert JJ, Eyster ME, Lederman MM, et al. 2002. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100:1584-89
19. Eyster ME, Fried MW, Di Bisceglie AM, et al. 1994. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 84:1020-23
20. Chung RT, Evans SR, Yang Y, et al. 2002. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 16:1915-23
21. Graham CS, Baden LR, Yu E, et al. 2001. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33:562-69
22. Bica I, McGovern B, Dhar R, et al. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32:492-97
23. Rosenthal E, Pialoux G, Bernard N, et al. 2007. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J. Viral Hepat. 14:183-88
24. Weber R, Sabin CA, Friis-Moller N, et al. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166:1632-41
25. Lohse N, Hansen AB, Pedersen G, et al. 2007. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 146:87-95
26. Sackoff JE, Hanna DB, Pfeiffer MR, et al. 2006. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann. Intern. Med. 145:397-406
27. Sulkowski MS, Thomas DL, Chaisson RE, et al. 2000. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 283:2526-27
28. McGovern BH, Ditelberg JS, Taylor LE, et al. 2006. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin. Infect. Dis. 43:365-72
29. Khella SL, Frost S, Hermann GA, et al. 1995. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review. Neurology 45:407-11
30. Benhamou Y, Bochet M, Di Martino V, et al. 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-58
31. Brau N, Salvatore M, Rios-Bedoya CF, et al. 2006. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol. 44:47-55
32. Qurishi N, Kreuzberg C, Luchters G, et al. 2004. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 362:1708-13
33. Strader DB, Wright T, Thomas DL, et al. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-71
34. Alberti A, Clumeck N, Collins S, et al. 2005. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. J. Hepatol. 42:615-24
35. Reichard O, Glaumann H, Fryden A, et al. 1999. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J. Hepatol. 30:783-87
36. Soriano V, Maida I, Nunez M, et al. 2004. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir. Ther. 9:987-92
37. Dominguez S, Ghosn J, Valantin MA, et al. 2006. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 20:1157-61
38. Carrat F, Bani-Sadr F, Pol S, et al. 2004. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839-48
39. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351:438-50
40. Chung RT, Andersen J, Volberding P, et al. 2004. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351:451-59
41. Laguno M, Murillas J, Blanco JL, et al. 2004. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 18:F27-36
42. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-55
43. Lissen E, Clumeck N, Sola R, et al. 2006. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus coinfection. AIDS 20:2175-81
44. Mauss S, Valenti W, Depamphilis J, et al. 2004. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18:F21-25
45. Alvarez D, Dieterich DT, Brau N, et al. 2006. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J. Viral Hepat. 13:683-89
46. Lafeuillade A, Hittinger G, Chadapaud S. 2001. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-81
47. Neff GW, Bonham A, Tzakis AG, et al. 2003. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 9:239-47
48. Mehta SH, Lucas GM, Mirel LB, et al. 2006. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20:2361-69
49. Lanford RE, Chavez D, Von Chisari F, et al. 1995. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J. Virol. 69:8079-83
50. Grakoui A, Shoukry NH, Woollard DJ, et al. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-62
51. Kim AY, Lauer GM, Ouchi K, et al. 2005. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 105:1170-78
52. Kim AY, Schulze zur WJ, Kuntzen T, et al. 2006. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3:e492
53. Netski DM, Mosbruger T, Astemborski J, et al. 2007. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J. Infect. Dis. 195:857-63
54. Balasubramanian A, Ganju RK, Groopman JE. 2006. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J. Infect. Dis. 194:670-81
55. Blackard JT, Kang M, Clair JB, et al. 2007. Viral factors associated with cytokine expression during HCV/HIV co-infection. J. Interferon Cytokine Res. 27:263-70
56. Greub G, Ledergerber B, Battegay M, et al. 2000. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800-5
57. Sulkowski MS, Moore RD, Mehta SH, et al. 2002. Hepatitis C and progression of HIV disease. JAMA 288:199-206
58. Contreras AM, Hiasa Y, He W, et al. 2002. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76:8505-17